142 related articles for article (PubMed ID: 36396022)
1. Modeling Tiered Pricing Frameworks: A Simulation Approach.
Moradpour J; Zhang W; Grootendorst P; Anis AH; Hollis A
Value Health; 2023 Mar; 26(3):351-358. PubMed ID: 36396022
[TBL] [Abstract][Full Text] [Related]
2. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
3. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
4. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Tiered-Pricing Framework on Generic Entry in Canada.
Zhang W; Sun H; Guh DP; Lynd LD; Hollis A; Grootendorst P; Anis AH
Int J Health Policy Manag; 2022 Jun; 11(6):768-776. PubMed ID: 33233033
[TBL] [Abstract][Full Text] [Related]
6. Optimal price regulations in international pharmaceutical markets with generic competition.
Geng D; Saggi K
J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
[TBL] [Abstract][Full Text] [Related]
7. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
8. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
9. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
10. Do pharmaceutical prices rise anticipating branded competition?
Ellyson AM; Basu A
Health Econ; 2021 May; 30(5):1070-1081. PubMed ID: 33684255
[TBL] [Abstract][Full Text] [Related]
11. A mixed integer programming model for vaccine pricing within a group purchasing organization.
Yu Z; Keskinocak P; Orenstein WA; Toktay LB
Vaccine; 2024 Mar; 42(8):1892-1898. PubMed ID: 37977944
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
13. The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies.
Cohen JT
Value Health; 2023 Mar; 26(3):344-350. PubMed ID: 36336585
[TBL] [Abstract][Full Text] [Related]
14. A comparison of generic drug prices in seven European countries: a methodological analysis.
Wouters OJ; Kanavos PG
BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
[TBL] [Abstract][Full Text] [Related]
15. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Brouwer ED; Basu A; Yeung K
Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
[TBL] [Abstract][Full Text] [Related]
16. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
17. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
Costa E; Santos C
Eur J Health Econ; 2022 Dec; 23(9):1497-1518. PubMed ID: 35192093
[TBL] [Abstract][Full Text] [Related]
19. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
20. Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs.
Jiang Y; Li M; Jiang S; Si L; Gu Y
Value Health; 2024 Mar; 27(3):273-277. PubMed ID: 38042332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
